Calluna Pharma
Founded 2024 · 26 employees on LinkedIn · 6 known investors
Completed patient enrollment in its Phase 2 AURORA trial.
Investors · 6
P53 InvestStavanger
Sarsia Management ASBergen · $190K – $475K
ForbionreportedNaarden
InvestinorreportedTrondheim
Also in the syndicate · 2
p53leadSarsialead
Funding
SEC filings, press & company announcements- Undisclosed amountSeries AJan 2024 · 3 sources
Forbion (lead), Investinor (lead), p53 (lead), Sarsia (lead)
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Competitors · 2
by search overlapBioworld4 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Laguna Biosciences Website3 shared keywordsLaguna Biotech is a biopharmaceutical company focused on discovering and developing new therapeutic approaches through science-driven research and clinical innovation.
Companies competing with Calluna Pharma for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Calluna Pharma do?
- Completed patient enrollment in its Phase 2 AURORA trial.
- Who are Calluna Pharma's investors?
- Calluna Pharma's investors include P53 Invest, Sarsia Management AS, Forbion, Investinor.